JP2014508734A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508734A5
JP2014508734A5 JP2013546764A JP2013546764A JP2014508734A5 JP 2014508734 A5 JP2014508734 A5 JP 2014508734A5 JP 2013546764 A JP2013546764 A JP 2013546764A JP 2013546764 A JP2013546764 A JP 2013546764A JP 2014508734 A5 JP2014508734 A5 JP 2014508734A5
Authority
JP
Japan
Prior art keywords
fluorocarbon
peptide
linked
formulation
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013546764A
Other languages
English (en)
Japanese (ja)
Other versions
JP6054302B2 (ja
JP2014508734A (ja
Filing date
Publication date
Priority claimed from GB201022147A external-priority patent/GB201022147D0/en
Application filed filed Critical
Publication of JP2014508734A publication Critical patent/JP2014508734A/ja
Publication of JP2014508734A5 publication Critical patent/JP2014508734A5/ja
Application granted granted Critical
Publication of JP6054302B2 publication Critical patent/JP6054302B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013546764A 2010-12-31 2011-12-30 フルオロカーボン連結ペプチド製剤 Expired - Fee Related JP6054302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201022147A GB201022147D0 (en) 2010-12-31 2010-12-31 Formulation
GB1022147.1 2010-12-31
PCT/GB2011/001781 WO2012090002A1 (en) 2010-12-31 2011-12-30 Fluorocarbon-linked peptide formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016153693A Division JP6279672B2 (ja) 2010-12-31 2016-08-04 フルオロカーボン連結ペプチド製剤

Publications (3)

Publication Number Publication Date
JP2014508734A JP2014508734A (ja) 2014-04-10
JP2014508734A5 true JP2014508734A5 (enExample) 2015-02-26
JP6054302B2 JP6054302B2 (ja) 2016-12-27

Family

ID=43638974

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013546764A Expired - Fee Related JP6054302B2 (ja) 2010-12-31 2011-12-30 フルオロカーボン連結ペプチド製剤
JP2016153693A Expired - Fee Related JP6279672B2 (ja) 2010-12-31 2016-08-04 フルオロカーボン連結ペプチド製剤
JP2018005604A Active JP6514373B2 (ja) 2010-12-31 2018-01-17 フルオロカーボン連結ペプチド製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016153693A Expired - Fee Related JP6279672B2 (ja) 2010-12-31 2016-08-04 フルオロカーボン連結ペプチド製剤
JP2018005604A Active JP6514373B2 (ja) 2010-12-31 2018-01-17 フルオロカーボン連結ペプチド製剤

Country Status (17)

Country Link
US (4) US9119811B2 (enExample)
EP (1) EP2658572B1 (enExample)
JP (3) JP6054302B2 (enExample)
KR (6) KR102356875B1 (enExample)
CN (2) CN105148265B (enExample)
AU (1) AU2011350997B2 (enExample)
BR (1) BR112013016870A2 (enExample)
CA (1) CA2823453C (enExample)
CL (1) CL2013001935A1 (enExample)
DK (1) DK2658572T3 (enExample)
EA (1) EA028396B1 (enExample)
ES (1) ES2645017T3 (enExample)
GB (2) GB201022147D0 (enExample)
IL (1) IL227273A0 (enExample)
MX (1) MX348954B (enExample)
WO (1) WO2012090002A1 (enExample)
ZA (1) ZA201305591B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
BR112019020853A2 (pt) 2017-04-04 2020-05-12 Avidea Technologies, Inc. Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
SG11201909572QA (en) 2017-04-18 2019-11-28 Alnylam Pharmaceuticals Inc Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
EP3820510A4 (en) 2018-07-10 2022-05-04 Seqirus Pty Ltd REMOVAL OF AGGLOMERATES
WO2022015662A1 (en) * 2020-07-12 2022-01-20 Altimmune, Inc Coronavirus immunogenic t cell epitope compositions and uses thereof
WO2024186890A1 (en) 2023-03-06 2024-09-12 Intellia Therapeutics, Inc. Compositions and methods for hepatitis b virus (hbv) genome editing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
EP1722819B1 (en) * 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Similar Documents

Publication Publication Date Title
JP2014508734A5 (enExample)
Luo et al. A powerful CD8+ T-cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant
JP2010500399A5 (enExample)
ES2643646T3 (es) Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
Bailey et al. Self-encapsulating poly (lactic-co-glycolic acid)(PLGA) microspheres for intranasal vaccine delivery
Wang et al. Ferritin nanocage-based antigen delivery nanoplatforms: epitope engineering for peptide vaccine design
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
RU2010114033A (ru) Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv
JP2008530245A5 (enExample)
CN110891592B (zh) 用于保护免受呼吸道合胞病毒的环状肽
JP2018521028A5 (enExample)
JP2012506411A5 (enExample)
EP3600396A1 (en) Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
Nguyen et al. Skin immunization with third-generation hepatitis B surface antigen using microneedles
Xu et al. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection
JP5766894B2 (ja) ワクチン増強剤としてのαチモシンペプチド
CN113491766A (zh) 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
Zhang et al. Silk Fibroin-Coated Nano-MOFs Enhance the Thermal Stability and Immunogenicity of HBsAg
BRPI0811692A2 (pt) material com imunogenicidade
JP2019534242A5 (enExample)
JP2020515283A5 (enExample)
JP2011524372A (ja) インフルエンザワクチン接種のための新規ペプチドアジュバント
CN107200788A (zh) 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
ES2363616T3 (es) Composiciones farmacéuticas que contienen anticuerpo monoclonal antidiotípico anti-ca125 y aluminio.
BR112019026336A2 (pt) forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico